Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - erlotinibklorid - filmom obložena tableta - 25 mg - urbroj: svaka filmom obložena tableta sadrži 25 mg erlotiniba (u obliku erlotinibklorida)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

actavis group ptc ehf., reykjavikurvegur 76-78, hafnarfjordur, island - erlotinibklorid - filmom obložena tableta - 100 mg - urbroj: jedna filmom obložena tableta sadrži 100 mg erlotiniba (u obliku erlotinibklorida)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

teva b.v., swensweg 5, haarlem, nizozemska - erlotinibklorid - filmom obložena tableta - 150 mg - urbroj: jedna filmom obložena tableta sadrži 150 mg erlotiniba (u obliku erlotinibklorida)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

actavis group ptc ehf., reykjavikurvegur 76-78, hafnarfjordur, island - erlotinibklorid - filmom obložena tableta - 25 mg - urbroj: jedna filmom obložena tableta sadrži 25 mg erlotiniba (u obliku erlotinibklorida)

Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - Ипилимумаб - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastična sredstva - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 i 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

gorea plus d.o.o. svetonedeljska cesta 97 10431 kerestinec -

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

gorea plus d.o.o. svetonedeljska cesta 97 10431 kerestinec -

Europska Unija - hrvatski - EMA (European Medicines Agency)

teva generics b.v - monohidrat zoledronske kiseline - osteoporosis; osteitis deformans - bisfosfonati - liječenje osteoporosisin post-menopausal žene za odrasle Менат povećanog rizika od prijeloma, uključujući i posljednjih padove-ozljede prijeloma kuka . liječenje osteoporoze, povezan s dugoj sistemske glukokortikoidni terapiju nakon menopauze žene za odrasle Менат povećanog rizika od prijeloma. liječenje pagetova bolest kostiju kod odraslih osoba.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, валсартан - zastoj srca - antagonisti angiotenzina ii, druge kombinacije, agenti koji djeluju na ренин-ангиотензиновую sustav - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, валсартан - zastoj srca - sredstva koja djeluju na sustav renin-angiotenzina - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.